AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8848324 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cm H2O of CPAP
Number of subjects: 10
Study 8848324 — intervention group
Group type: COMPARATOR
Intervention: Zero end-expiratory pressure
Number of subjects: 10
Study 1320887 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin (CsA) at a dose of 7.5-10 mg/day for the first 6 months, then not exceeding 5 mg/kg/day thereafter
Number of subjects: 49
Study 1320887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 6392148 — intervention group
Group type: EXPERIMENTAL
Intervention: DTIC plus epirubicin (Epi‐DX) at a dose of 90 mg/m2 on day 1
Number of subjects: 42
Study 6392148 — intervention group
Group type: COMPARATOR
Intervention: DTIC at a dose of 250 mg/m2/day 4 IV on days 1‐5
Number of subjects: 42
Study 30165053 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored program of physical therapy focused on progressive training in strength, balance, and gait for a period of 3 months, including screening and referrals for low vision, polypharmacy, and environmental hazards.
Number of subjects: 354
Study 30165053 — intervention group
Group type: COMPARATOR
Intervention: Usual care prescribed by a physician and educational materials on falls prevention.
Number of subjects: 354
Study 29453502 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenting Wisely program (various formats)
Number of subjects: 311
Study 29453502 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 311
Study 26178580 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (5000 IU) + Calcium (600 mg)
Number of subjects: 20
Study 26178580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Calcium alone)
Number of subjects: 20
Study 26311340 — intervention group
Group type: COMPARATOR
Intervention: VARD (Group A; n=19)
Number of subjects: 30
Study 26311340 — intervention group
Group type: EXPERIMENTAL
Intervention: VARD+CBST (Group B; n=11)
Number of subjects: 30
Study 23896665 — intervention group
Group type: COMPARATOR
Intervention: 30-cm intermittent catheter
Number of subjects: 81
Study 23896665 — intervention group
Group type: EXPERIMENTAL
Intervention: 40-cm intermittent catheter
Number of subjects: 81
Study 22015095 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg per day)
Number of subjects: 22
Study 22015095 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 22015095 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg per day) in severe urticaria subgroup
Number of subjects: 22
Study 22015095 — intervention group
Group type: COMPARATOR
Intervention: Placebo in severe urticaria subgroup
Number of subjects: 22
Study 18278702 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis
Number of subjects: 0
Study 16957082 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative connectivity within cortical and subcortical pathways to the amygdala
Number of subjects: 0
Study 16957082 — intervention group
Group type: COMPARATOR
Intervention: Positive connections in a direct subcortical pathway to the amygdala
Number of subjects: 0
Study 12684361 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (n = 30)
Number of subjects: 60
Study 12684361 — intervention group
Group type: EXPERIMENTAL
Intervention: Zonisamide (n = 19)
Number of subjects: 60
Study 12684361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 30)
Number of subjects: 60
Study 12684361 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 17)
Number of subjects: 60
Study 10959805 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 or 9 million units (MU) interferon three times a week for 6 months (total dose: 468 or 702 MU)
Number of subjects: 114
Study 10959805 — intervention group
Group type: EXPERIMENTAL
Intervention: 6MU of IFN over 6 months (total dose 564 MU)
Number of subjects: 114
Study 10959805 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 or 9 MU of IFN three times a week for 12 months (total dose: 936 or 1,404 MU)
Number of subjects: 114
Study 8960446 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (200 mg three times daily)
Number of subjects: 81
Study 8960446 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate
Number of subjects: 81
Study 8960446 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study 8169401 — intervention group
Group type: EXPERIMENTAL
Intervention: Zidovudine (200 mg every 8 h) and fluconazole (400 mg daily) for 7 days
Number of subjects: 12
Study 8169401 — intervention group
Group type: COMPARATOR
Intervention: Zidovudine alone
Number of subjects: 12
Study 2467134 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5-10.0 mg daily
Number of subjects: 30
Study 2467134 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 29265358 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooperative Learning (CL) intervention
Number of subjects: 1460
Study 27442085 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus 1.2% Atorvastatin (ATV)
Number of subjects: 75
Study 27442085 — intervention group
Group type: COMPARATOR
Intervention: SRP plus placebo
Number of subjects: 75
Study 25706516 — intervention group
Group type: EXPERIMENTAL
Intervention: AOK-proReha treatment approach
Number of subjects: 619
Study 24717954 — intervention group
Group type: EXPERIMENTAL
Intervention: Quantic molecular resonance (QMR) inferior turbinoplasty in addition to standard medical treatment (ebastine, 10-mg tablet, and budesonide nasal spray at 100 micrograms/nostril per day for 90 days)
Number of subjects: 290
Study 24717954 — intervention group
Group type: COMPARATOR
Intervention: Standard medical treatment (ebastine, 10-mg tablet, and budesonide nasal spray at 100 micrograms/nostril per day for 90 days)
Number of subjects: 290
Study 22648087 — intervention group
Group type: EXPERIMENTAL
Intervention: Staccato reperfusion plus statin therapy (SRSG)
Number of subjects: 47
Study 22648087 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin therapy plus abrupt reperfusion (SG)
Number of subjects: 47
Study 22648087 — intervention group
Group type: COMPARATOR
Intervention: Abrupt reperfusion alone (ARG)
Number of subjects: 47
Study 20805570 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated software analysis of corneal micrographs
Number of subjects: 0
Study 18596271 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1 mg of epinephrine and 40 IU of vasopressin
Number of subjects: 2894
Study 18596271 — intervention group
Group type: COMPARATOR
Intervention: Epinephrine alone (1 mg)
Number of subjects: 2894
Study 15963746 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 40
Study 15963746 — intervention group
Group type: COMPARATOR
Intervention: Gelofusine
Number of subjects: 40
Study 11933905 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal-cycling at an upper temperature of 60 degrees C
Number of subjects: 18
Study 11933905 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal-cycling at an upper temperature of 45 degrees C
Number of subjects: 18
Study 11933905 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal-cycling (both 45 degrees C and 60 degrees C)
Number of subjects: 18
Study 11933905 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 18
Study 11933905 — intervention group
Group type: EXPERIMENTAL
Intervention: Z100 and Surefil
Number of subjects: 18
Study 11933905 — intervention group
Group type: EXPERIMENTAL
Intervention: Thermal-cycling
Number of subjects: 18
Study 9878938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 120 IU/kg body weight twice daily
Number of subjects: 175
Study 9878938 — intervention group
Group type: EXPERIMENTAL
Intervention: Dalteparin 7500 IU once daily (fixed dose)
Number of subjects: 175
Study 9878938 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight-adjusted treatment
Number of subjects: 175
Study 9878938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed dose treatment
Number of subjects: 175
Study 9878938 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute phase treatment
Number of subjects: 175
Study 9878938 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose treatment
Number of subjects: 175
Study 8822685 — intervention group
Group type: EXPERIMENTAL
Intervention: Expiratory muscle training
Number of subjects: 20
Study 8822685 — intervention group
Group type: COMPARATOR
Intervention: Sham training
Number of subjects: 20
Study 1414432 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal sponge use
Number of subjects: 72
Study 1414432 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 72
Study 4012191 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunarizine (15 mg nocte)
Number of subjects: 30
Study 4012191 — intervention group
Group type: COMPARATOR
Intervention: Pizotifen (1.5 mg nocte)
Number of subjects: 30
Study 30590467 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan
Number of subjects: 26
Study 30590467 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 26
Study 28836866 — intervention group
Group type: EXPERIMENTAL
Intervention: Azacitidine (Aza)
Number of subjects: 36
Study 28836866 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care (BSC)
Number of subjects: 36
Study 26768928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex) 6 μg/kg/h for 10 min followed by 0.4 μg/kg/h until 5 min after extubation
Number of subjects: 70
Study 26768928 — intervention group
Group type: COMPARATOR
Intervention: Saline (control) administered in a similar manner to Dex
Number of subjects: 70
Study 26768928 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (Dex)
Number of subjects: 70
Study 26768928 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 70
Study 24506231 — intervention group
Group type: EXPERIMENTAL
Intervention: Client-centred activities of daily living (CADL) intervention
Number of subjects: 280
Study 24506231 — intervention group
Group type: COMPARATOR
Intervention: Usual activities of daily living (UADL) intervention
Number of subjects: 280
Study 22678673 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of akatinol memantine 20 mg in the morning
Number of subjects: 40
Study 22678673 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with two doses of akatinol memantine (10 mg in the morning and 10 mg in the afternoon)
Number of subjects: 40
Study 20847991 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediately loaded implants
Number of subjects: 52
Study 20847991 — intervention group
Group type: COMPARATOR
Intervention: Early loaded implants
Number of subjects: 52
Study 20847991 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 17873686 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX 380 mg
Number of subjects: 82
Study 17873686 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 17873686 — intervention group
Group type: EXPERIMENTAL
Intervention: XR-NTX 190 mg
Number of subjects: 82
Study 16383037 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 150 mg diammonium glycyrrhizinate per day for 14 days (T group)
Number of subjects: 20
Study 16383037 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (C group)
Number of subjects: 20
Study 12357876 — intervention group
Group type: EXPERIMENTAL
Intervention: True feed (cow's milk)
Number of subjects: 154
Study 12357876 — intervention group
Group type: COMPARATOR
Intervention: Placebo meals
Number of subjects: 154
Study 10430680 — intervention group
Group type: EXPERIMENTAL
Intervention: Bipolar cutting forceps (BPCF)
Number of subjects: 86
Study 10430680 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic coagulating shears (HCS)
Number of subjects: 86
Study 7593517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin (200 micrograms twice daily as a nasal spray)
Number of subjects: 188
Study 7593517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 188
Study 7593517 — intervention group
Group type: EXPERIMENTAL
Intervention: Nafarelin
Number of subjects: 188
Study 1351705 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 10 micrograms/kg with neostigmine 40 micrograms/kg
Number of subjects: 36
Study 1351705 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 15 micrograms/kg with neostigmine 40 micrograms/kg
Number of subjects: 36
Study 1351705 — intervention group
Group type: EXPERIMENTAL
Intervention: Atropine 20 micrograms/kg with neostigmine 40 micrograms/kg
Number of subjects: 36
Study 1351705 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as no atropine)
Number of subjects: 36
Study 3833371 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid capsules (1 mg)
Number of subjects: 18
Study 3833371 — intervention group
Group type: COMPARATOR
Intervention: Oral tablets (1 mg)
Number of subjects: 18
Study 3833371 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 18
Study 3833371 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid capsules
Number of subjects: 18
Study 29521723 — intervention group
Group type: EXPERIMENTAL
Intervention: Large Balloon Dilation (LBD)
Number of subjects: 98
Study 29521723 — intervention group
Group type: COMPARATOR
Intervention: Mechanical Lithotripsy (ML)
Number of subjects: 98
Study 29521723 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 98
Study 29476847 — intervention group
Group type: EXPERIMENTAL
Intervention: Double high-level disinfection (HLD)
Number of subjects: 2925
Study 29476847 — intervention group
Group type: COMPARATOR
Intervention: Single high-level disinfection (HLD)
Number of subjects: 2925
Study 26885787 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapsone 5% gel (twice daily) with oral doxycycline hyclate 100mg (once daily) for 12 weeks, followed by dapsone 5% gel (twice daily) for 12 weeks
Number of subjects: 30
Study 25282345 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother‐Infant Transaction Program (MITP)
Number of subjects: 146
Study 25282345 — intervention group
Group type: COMPARATOR
Intervention: Preterm control group (standard hospital care)
Number of subjects: 146
Study 22938706 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiotropium (5 μg once daily for 48 weeks)
Number of subjects: 912
Study 22938706 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once daily for 48 weeks)
Number of subjects: 912
Study 20920800 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga (12 weekly 75-min sessions plus written advice)
Number of subjects: 20
Study 20920800 — intervention group
Group type: COMPARATOR
Intervention: Usual care (plus written advice)
Number of subjects: 20
Study 17608255 — intervention group
Group type: EXPERIMENTAL
Intervention: Boussignac CPAP
Number of subjects: 19
Study 17608255 — intervention group
Group type: COMPARATOR
Intervention: Nasal catheter (control)
Number of subjects: 19
Study 16060739 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical position in space (intervention)
Number of subjects: 0
Study 16060739 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor responses implying vertical movement (intervention)
Number of subjects: 0
Study 16060739 — intervention group
Group type: EXPERIMENTAL
Intervention: Vertical position (intervention)
Number of subjects: 0
Study 16060739 — intervention group
Group type: COMPARATOR
Intervention: N/A (control)
Number of subjects: 0
Study 12012079 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate supplement (0.3 g x kg(‐1) of body mass)
Number of subjects: 10
Study 12012079 — intervention group
Group type: COMPARATOR
Intervention: Placebo mixture
Number of subjects: 10
Study 12012079 — intervention group
Group type: EXPERIMENTAL
Intervention: Bicarbonate supplement
Number of subjects: 10
Study 10078718 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine 1,200 mg twice daily
Number of subjects: 0
Study 10078718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7549384 — intervention group
Group type: EXPERIMENTAL
Intervention: Zhengda Zhenhua 851‐R oral liquor
Number of subjects: 0
Study 7549384 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2154855 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin plus etoposide (cisplatin 120 mg/m2, etoposide 100 mg/m2, days 1 to 3)
Number of subjects: 162
Study 2154855 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin plus etoposide (carboplatin 325 mg/m2, etoposide 100 mg/m2, days 1 to 3)
Number of subjects: 162
Study 389813 — intervention group
Group type: EXPERIMENTAL
Intervention: 410 mg sulphadiazine + 90 mg trimethoprim (SD + TMP)
Number of subjects: 78
Study 389813 — intervention group
Group type: COMPARATOR
Intervention: 800 mg sulphamethoxazole + 160 mg trimethoprim (SMZ + TMP)
Number of subjects: 78
Study 31005968 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cystathionine levels in patients with SAP
Number of subjects: 6703
Study 31005968 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma cystathionine levels in patients with AMI
Number of subjects: 6703
Study 28855224 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 fatty acid preparation (1.7 g DHA and 0.6 g EPA daily for 6 months)
Number of subjects: 63
Study 28855224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 26461872 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue collar workers
Number of subjects: 1700
Study 26461872 — intervention group
Group type: EXPERIMENTAL
Intervention: Service workers
Number of subjects: 1700
Study 26461872 — intervention group
Group type: EXPERIMENTAL
Intervention: Service and blue collar workers
Number of subjects: 1700
Study 26461872 — intervention group
Group type: EXPERIMENTAL
Intervention: White collar workers
Number of subjects: 1700
Study 23416815 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional Endoscopic Sinus Surgery (FESS)
Number of subjects: 60
Study 23416815 — intervention group
Group type: COMPARATOR
Intervention: Conventional surgical procedure
Number of subjects: 60
Study 21813074 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 160
Study 21813074 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine/+valproic acid
Number of subjects: 160
Study 21813074 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone/+valproic acid
Number of subjects: 160
Study 20001608 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-positive patients with HAD
Number of subjects: 33
Study 20001608 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with HAD
Number of subjects: 33
Study 20001608 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV controls
Number of subjects: 33
Study 17419010 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolic stressor
Number of subjects: 29
Study 17419010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 15448205 — intervention group
Group type: EXPERIMENTAL
Intervention: PKC412 (N‐benzoyl‐staurosporine)
Number of subjects: 1
Study 11306214 — intervention group
Group type: EXPERIMENTAL
Intervention: Methadone treatment interventions
Number of subjects: 150
Study 9337190 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 557
Study 9337190 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 557
Study 7957502 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral treatment with DDAVP
Number of subjects: 7
Study 7957502 — intervention group
Group type: EXPERIMENTAL
Intervention: Endonasal treatment with DDAVP
Number of subjects: 7
Study 7957502 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 7
Study 3661642 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of nadolol twice daily
Number of subjects: 17
Study 3661642 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of nadolol twice daily
Number of subjects: 17
Study 3661642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 31490858 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy-periodized exercise prescription
Number of subjects: 27
Study 31490858 — intervention group
Group type: COMPARATOR
Intervention: Standard linear exercise prescription
Number of subjects: 27
Study 30070193 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of healthy foods sold from school canteens (intervention from a larger RCT)
Number of subjects: 50
Study 28431543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty (type Müller Straight Stem)
Number of subjects: 201
Study 28431543 — intervention group
Group type: COMPARATOR
Intervention: Uncemented hemiarthroplasty (type DB‐10)
Number of subjects: 201
Study 28431543 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented hemiarthroplasty
Number of subjects: 201
Study 28431543 — intervention group
Group type: COMPARATOR
Intervention: Uncemented hemiarthroplasty
Number of subjects: 201
Study 25322952 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic nasobiliary drainage (ENBD) after endoscopic papillary balloon dilation (EPBD)
Number of subjects: 93
Study 25322952 — intervention group
Group type: COMPARATOR
Intervention: No endoscopic nasobiliary drainage (No-ENBD) after endoscopic papillary balloon dilation (EPBD)
Number of subjects: 93
Study 25322952 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (ENBD and No-ENBD)
Number of subjects: 93
Study 23739025 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BUP)
Number of subjects: 1269
Study 23739025 — intervention group
Group type: COMPARATOR
Intervention: Methadone
Number of subjects: 1269
Study 23739025 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine/naloxone (BUP) and Methadone
Number of subjects: 1269
Study 20547668 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training programme (dynamic stretching, eccentric strength, agility, jumping, balance, home-based balance training with a wobble board)
Number of subjects: 744
Study 20547668 — intervention group
Group type: COMPARATOR
Intervention: Standardised warm-up (static and dynamic stretching, aerobic components) and home-based stretching programme
Number of subjects: 744
Study 20547668 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training programme
Number of subjects: 744
Study 18406165 — intervention group
Group type: EXPERIMENTAL
Intervention: Liquid formulation of IV RhIG (300 microg IM in Study 1; 15 microg/kg IM in Study 2; 50 microg/kg IV in Study 1)
Number of subjects: 142